1. P282 High plasma oncostatin-M predicts non-response to tumour necrosis factor-alpha antagonists in inflammatory bowel disease. (27th May 2021) Authors: Guo, A; Ross, C; Chande, N; Gregor, J; Ponich, T; Beaton, M; Khanna, R; Kim, R; Wilson, A Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P544 Patients with moderate to severe Crohn's disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials. (21st January 2022) Authors: D'Haens, G; Beaton, M; Bossuyt, P; Dotan, I; Sands, B; Sugimoto, K; Neimark, E; Song, A; Wallace, K; Zhou, Q; Kligys, K; Ferrante, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i491 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis. (30th January 2023) Authors: Jairath, V; Zou, G; Wang, Z; Adsul, S; Colombel, J F; D'Haens, G R; Freire, M; Moran, G W; Peyrin-Biroulet, L; Sandborn, W J; Sebastian, S; Travis, S; Vermeire, S; Radulescu, G; Sigler, J; Mcfarlane, S; Arya, N; Beaton, M; Bossuyt, P; Green, D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗